Immunic to Participate in Investor Conferences in November
NEW YORK, Nov. 2, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor conferences in November: November 9-11: Guggenheim...